Recommended Guardant Reveal testing schedule
for colorectal, breast, and lung cancers4-6:
SURVEILLANCE
Easily integrate
MRD testing to complement existing guideline-recommended surveillance.1-3*
Germline testing is available for add-on ordering.
Talk to a Guardant Health representative to learn more.
CEA, carcinoembryonic antigen; CT, computerized tomography;
ctDNA, circulating tumor DNA; MRD, minimal residual disease.
Important note: Guardant Reveal was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.
*For invasive carcinomas and inflammatory breast cancers and non-small cell lung cancer (adenocarcinoma, large cell, and squamous).